Device Devices

Gore Cardioform Septal Occluder

Payments companies reported to CMS as associated with Gore Cardioform Septal Occluder. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.3Massociated payments (2023-2025)
2,330clinicians with associated payments
1company reporting

By year

2023 $437K
2024 $470K
2025 $433K

Payments reported as associated with Gore Cardioform Septal Occluder, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Interventional Cardiology $630K
Pediatric Cardiology $298K
Cardiovascular Disease $262K
Internal Medicine $18K
Vascular Neurology $18K
Adult Congenital Heart Disease $16K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Gore Cardioform Septal Occluder

These are the largest totals companies reported as associated with Gore Cardioform Septal Occluder. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Matthew Gillespie Philadelphia, PA Pediatric Cardiology $64,766.33
Vamsee Yaganti Salt Lake City, UT Interventional Cardiology $61,304.39
William Crowder Jackson, MS Interventional Cardiology $60,963.90
Islam Abudayyeh Redlands, CA Interventional Cardiology $60,831.76
Joseph Paolillo Charlotte, NC Pediatric Cardiology $58,763.32
Bibhu Mohanty Tampa, FL Interventional Cardiology $50,029.54
Brent Gordon San Diego, CA Pediatric Cardiology $46,398.36
Gagan Singh Sacramento, CA Cardiovascular Disease $46,381.42
John Lasala Saint Louis, MO Interventional Cardiology $45,620.08
Joanna Ghobrial Los Angeles, CA Cardiovascular Disease $41,562.90

Prescribed Gore Cardioform Septal Occluder?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.